Pathways underlying myopia (nearsightedness) and hyperopia (farsightedness) are different, not opposite, revealed study published in journal PLOS Biology and conducted by Andrei Tkatchenko of Columbia University and colleagues.
Myopia occurs when the eye grows too long, increasing the distance between lens and retina such that the image produced by the lens comes into focus at a point in front of, rather than on, the retina. In hyperopia, the opposite occurs; the eye is too short, and the focal point is behind the retina. While prolonged "nearwork" such as reading or sewing increases the risk of myopia, neither the molecular pathways underlying its development, nor those driving hyperopia, are well known.
Myopia is expected to affect nearly half the world's population in the next three decades. To explore those pathways, the authors induced either myopia or hyperopia in marmosets, by placing lenses in front of their eyes. A lens that shifts the focal point to behind the retina ("hyperopic defocus") induces myopia, while one that shifts it to in front of the retina ("myopic defocus") induces hyperopia. In each case, the eye changes shape, elongating or shortening, to compensate by moving the retina closer to the focal point.
There were also gene activity differences over time in each type, with little overlap between those affected within the first 10 days and those affected after 5 weeks. Importantly, the authors found that 29 of the genes whose activity changed in response to defocus were localized within chromosomal regions (called quantitative trait loci) previously associated with human myopia in large-scale genetic studies, suggesting that variations in the expression of genes involved in the normal regulation of eye shape in response to defocus contribute to nearsightedness.
"The results of this study show that the retina can distinguish between myopic and hyperopic defocus and responds to defocus of opposite signs by activating largely distinct pathways," Tkatchenko said. "Identification of these pathways provides a framework for the identification of new drug targets and for the development of more effective treatment options for myopia."